Skip to content

Cicatrix Cream in cutaneous striae

Clinical trial phase II Efficacy of the Cicatrix Cream in the treatment of cutaneous striae

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
RPCEC
Registry ID
RPCEC00000090
Enrollment
Unknown
Registered
2009-10-23
Start date
2009-09-09
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous striae

Interventions

There will be topical application of the product (Cicatrix cream) 3 times daily for 4 months. The dose will be 0,1 ml per centimetre of surface because the product will apply locally in the form of a

Sponsors

Catalysis SL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patient with cutaneous striae Patients aged 10 years and 18 years of both sexes (ID card) Signed the Informed consent

Exclusion criteria

Exclusion criteria: Patient that refer manifestations of high sensibility to the medication or to some of the. components of the product Patient that don’t want to participate in the study Patient not very cooperative Responsible family not very cooperative

Design outcomes

Primary

MeasureTime frame
Evaluation of the striaes (Excellent (E) Disappearance the striaes to the 4 months of initiate the treatment, Good (B): Disappearance of the striaes more than 50 %, Regular (R): Disappearance of the striaes less than 50 %, Bad (M): That stays the clinical square without variation). Measurement time: monthly for 4 months.

Secondary

MeasureTime frame
Extension and reduction of the striaes expressed in centimetres (Good: Reduction of more than 50% in centimeters, Regular: Reduction of less than 50% in centimetres, Bad: No reduction). Measurement time: monthly for 4 months Security depends of the Adverse Events (AE)(Good: without AE, Regular: There are AE but it is possible to continue the treatment, Bad: Interruption of the treatment due AE). Measurement time: monthly for 4 months.

Countries

Cuba

Contacts

Public ContactFernanda Pastrana

Pediatric Hospital "Juan Manuel Marquez"

fpastrana@infomed.sld.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Aug 15, 2026